Target Price | $35.70 |
Price | $25.98 |
Potential |
37.41%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Summit Therapeutics PLC Sponsored ADR 2026 .
The average Summit Therapeutics PLC Sponsored ADR target price is $35.70.
This is
37.41%
register free of charge
$46.20
77.83%
register free of charge
$12.12
53.35%
register free of charge
|
|
A rating was issued by 19 analysts: 16 Analysts recommend Summit Therapeutics PLC Sponsored ADR to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Summit Therapeutics PLC Sponsored ADR stock has an average upside potential 2026 of
37.41%
register free of charge
|
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 27 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
Analyst Rating | Date |
---|---|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 04 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 02 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 27 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 15 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.